Alimera Sciences reports Q2 EPS (6c), consensus (4c)

Reports Q2 revenue $27M, consensus $25.73M. We are pleased with our strong second quarter results, in line with our expectations, as we completed the integration of YUTIQ into our U.S. business and delivered $50 million in revenue in the first half this year,” said Rick Eiswirth, Alimeras President and Chief Executive Officer. “Further, we believe the acquisition agreement entered into with ANI Pharmaceuticals late in the second quarter is a testament to the value we have created at Alimera, and we look forward to completing the transaction later this quarter.”